Drug Profile

Omalizumab biosimilar - Biosana Pharma

Alternative Names: AVT 23; BP-001

Latest Information Update: 06 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biosana Pharma
Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action IgE receptor antagonists; Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Asthma
Discontinued Chronic urticaria

Most Recent Events

06 Nov 2024 Discontinued - Phase-I for Chronic-urticaria (In volunteers) in Australia (SC) (Alvotech pipeline, November 2024)
05 Nov 2024 Phase I development is ongoing in Australia for Asthma
28 Sep 2024 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Australia (SC, Injection)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com